|
AU2018244935A1
(en)
*
|
2017-03-30 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Naphthyridines as inhibitors of HPK1
|
|
JP6836693B2
(ja)
*
|
2017-09-28 |
2021-03-03 |
シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッドＣｓｔｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｓｕｚｈｏｕ） Ｃｏ．， Ｌｔｄ． |
Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
|
|
EP3707138B1
(en)
|
2017-11-06 |
2022-07-13 |
Bristol-Myers Squibb Company |
Isofuranone compounds useful as hpk1 inhibitors
|
|
CR20200347A
(es)
|
2018-02-13 |
2020-09-23 |
Gilead Sciences Inc |
Inhibidores pd-1/pd-l1
|
|
EP3765459A1
(en)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
TWI712412B
(zh)
|
2018-04-19 |
2020-12-11 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
SG11202012425QA
(en)
|
2018-07-13 |
2021-01-28 |
Gilead Sciences Inc |
Pd-1/pd-l1 inhibitors
|
|
TW202012405A
(zh)
*
|
2018-07-24 |
2020-04-01 |
瑞士商赫孚孟拉羅股份公司 |
萘啶化合物及其用途
|
|
EP3856724A1
(en)
*
|
2018-09-30 |
2021-08-04 |
F. Hoffmann-La Roche AG |
Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer
|
|
US11203591B2
(en)
|
2018-10-31 |
2021-12-21 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
WO2020120257A1
(en)
|
2018-12-11 |
2020-06-18 |
Bayer Aktiengesellschaft |
Substituted pyrrolopyridine-derivatives
|
|
US12492194B2
(en)
|
2019-03-26 |
2025-12-09 |
Janssen Pharmaceutica Nv |
HPK1 inhibitors
|
|
US12486264B2
(en)
|
2019-03-26 |
2025-12-02 |
Janssen Pharmaceutica Nv |
Bicyclic HPK1 inhibitors
|
|
EP3972695A1
(en)
|
2019-05-23 |
2022-03-30 |
Gilead Sciences, Inc. |
Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
|
|
WO2020263830A1
(en)
|
2019-06-25 |
2020-12-30 |
Gilead Sciences, Inc. |
Flt3l-fc fusion proteins and methods of use
|
|
TWI848141B
(zh)
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
TW202116753A
(zh)
*
|
2019-07-11 |
2021-05-01 |
大陸商南京征祥醫藥有限公司 |
以噌啉作為hpk1的抑制劑
|
|
US12459958B2
(en)
|
2019-07-17 |
2025-11-04 |
Beone Medicines I Gmbh |
Tricyclic compounds as HPK1 inhibitor and the use thereof
|
|
CN110483402B
(zh)
*
|
2019-08-12 |
2021-07-23 |
上海毕得医药科技股份有限公司 |
一种3-溴-5-苯基-1h-吡唑的合成方法
|
|
WO2021032148A1
(en)
*
|
2019-08-21 |
2021-02-25 |
Beigene, Ltd. |
Aminopyrazine compounds as hpk1 inhibitor and the use thereof
|
|
MX2022002877A
(es)
*
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
|
DK4031547T3
(da)
|
2019-09-18 |
2024-09-09 |
Takeda Pharmaceuticals Co |
Plasmakallikreininhibitorer og anvendelser deraf
|
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
ES2973832T3
(es)
|
2019-10-18 |
2024-06-24 |
Forty Seven Inc |
Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
|
|
JP2022552748A
(ja)
|
2019-10-31 |
2022-12-19 |
フォーティ セブン， インコーポレイテッド |
抗ｃｄ４７及び抗ｃｄ２０による血液癌の治療
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
IL294032A
(en)
|
2019-12-24 |
2022-08-01 |
Carna Biosciences Inc |
Compounds that regulate diacylglycerol kinase
|
|
TW202140473A
(zh)
*
|
2020-01-15 |
2021-11-01 |
美商纜圖藥品公司 |
Map4k1抑制劑
|
|
TWI890283B
(zh)
|
2020-02-14 |
2025-07-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
CN113336747A
(zh)
*
|
2020-03-03 |
2021-09-03 |
轶诺(浙江)药业有限公司 |
新型hpk1抑制剂及其制备方法和应用
|
|
IL297327B2
(en)
|
2020-05-01 |
2026-01-01 |
Gilead Sciences Inc |
4,2-dioxopyrimidine compounds CD73 inhibitors
|
|
WO2021249913A1
(en)
|
2020-06-09 |
2021-12-16 |
Bayer Aktiengesellschaft |
2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
|
|
CN111965367A
(zh)
*
|
2020-07-23 |
2020-11-20 |
北京大学第三医院（北京大学第三临床医学院） |
Hip-55在作为gpcr偏向药物靶点中的应用
|
|
WO2022064459A1
(en)
*
|
2020-09-28 |
2022-03-31 |
1ST Biotherapeutics, Inc. |
Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same
|
|
US20240174683A1
(en)
|
2021-02-05 |
2024-05-30 |
Bayer Aktiengesellschaft |
Map4k1 inhibitors
|
|
CN114907374B
(zh)
*
|
2021-02-07 |
2026-03-10 |
苏州信诺维医药科技股份有限公司 |
杂环化合物、其制备方法、药物组合物及应用
|
|
CN114907375B
(zh)
*
|
2021-02-07 |
2026-03-31 |
苏州信诺维医药科技股份有限公司 |
杂环化合物、其制备方法、药物组合物及应用
|
|
EP4291235A4
(en)
|
2021-02-12 |
2025-01-08 |
Nimbus Saturn, Inc. |
HPK1 ANTAGONISTS AND USES THEREOF
|
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
|
CN115073308A
(zh)
*
|
2021-03-15 |
2022-09-20 |
苏州信礼发医药技术有限公司 |
1-氨甲基-1-环丙醇的合成方法
|
|
JP2024512497A
(ja)
*
|
2021-03-17 |
2024-03-19 |
武田薬品工業株式会社 |
血漿カリクレインの阻害剤
|
|
WO2022213062A1
(en)
|
2021-03-29 |
2022-10-06 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
|
TW202304434A
(zh)
*
|
2021-04-08 |
2023-02-01 |
大陸商杭州阿諾生物醫藥科技有限公司 |
一種高活性的ｈｐｋ１激酶抑制劑
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
WO2022222951A1
(zh)
*
|
2021-04-22 |
2022-10-27 |
浙江海正药业股份有限公司 |
芳香稠合环类衍生物及其制备方法和用途
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
AU2022299051B2
(en)
|
2021-06-23 |
2025-03-13 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
JP7651018B2
(ja)
|
2021-06-23 |
2025-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
JP7686091B2
(ja)
|
2021-06-23 |
2025-05-30 |
ギリアード サイエンシーズ， インコーポレイテッド |
ジアシルグリセロールキナーゼ調節化合物
|
|
MX2023014762A
(es)
|
2021-06-23 |
2024-01-15 |
Gilead Sciences Inc |
Compuestos moduladores de diacilglicerol quinasa.
|
|
WO2023288254A1
(en)
*
|
2021-07-14 |
2023-01-19 |
Blueprint Medicines Corporation |
Heterocyclic compounds as map4k1 inhibitors
|
|
AU2022375782B2
(en)
|
2021-10-28 |
2026-02-26 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US12122764B2
(en)
|
2021-12-22 |
2024-10-22 |
Gilead Sciences, Inc. |
IKAROS zinc finger family degraders and uses thereof
|
|
KR20240123836A
(ko)
|
2021-12-22 |
2024-08-14 |
길리애드 사이언시즈, 인코포레이티드 |
이카로스 아연 핑거 패밀리 분해제 및 이의 용도
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023178181A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
KR20240165995A
(ko)
|
2022-03-24 |
2024-11-25 |
길리애드 사이언시즈, 인코포레이티드 |
Trop-2 발현 암의 치료를 위한 병용요법
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023193759A1
(en)
*
|
2022-04-07 |
2023-10-12 |
Insilico Medicine Ip Limited |
Hpk1 antagonists and uses thereof
|
|
CR20240451A
(es)
|
2022-04-21 |
2024-12-04 |
Gilead Sciences Inc |
Compuestos de modulación de kras g12d
|
|
EP4539840A4
(en)
*
|
2022-06-17 |
2026-04-15 |
Sundance Biosciences Inc |
Kinase Modulators and Their Methods of Use
|
|
WO2024003773A1
(en)
*
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
KR20250028371A
(ko)
|
2022-07-01 |
2025-02-28 |
길리애드 사이언시즈, 인코포레이티드 |
Cd73 화합물
|
|
EP4590663A2
(en)
*
|
2022-09-21 |
2025-07-30 |
Takeda Pharmaceutical Company Limited |
Synthesis of cyclopropane carboxylic acids
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
US20260092074A1
(en)
*
|
2022-09-23 |
2026-04-02 |
Guangzhou Vinnocent Pharmaceutical Limited |
Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
AU2024252725A1
(en)
|
2023-04-11 |
2025-11-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CR20250446A
(es)
|
2023-04-21 |
2025-12-02 |
Gilead Sciences Inc |
Inhibidores de prmt5 y usos de los mismos
|
|
WO2024243025A1
(en)
*
|
2023-05-19 |
2024-11-28 |
Ikena Oncology, Inc. |
Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions
|
|
AU2024306338A1
(en)
|
2023-06-30 |
2026-01-08 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
KR20260046403A
(ko)
|
2023-07-26 |
2026-04-07 |
길리애드 사이언시즈, 인코포레이티드 |
Parp7 저해제
|
|
CN121620513A
(zh)
|
2023-07-26 |
2026-03-06 |
吉利德科学公司 |
Parp7抑制剂
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250109147A1
(en)
|
2023-09-08 |
2025-04-03 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260098049A1
(en)
|
2024-08-12 |
2026-04-09 |
Gilead Sciences, Inc. |
Kras modulating compounds
|